OTCMKTS:ELOX - Eloxx Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$9.43 -0.34 (-3.48 %)
(As of 05/24/2019 04:00 PM ET)
Previous Close$9.77
Today's Range$9.09 - $10.14
52-Week Range$9.09 - $24.60
Volume30,500 shs
Average Volume30,228 shs
Market Capitalization$339.72 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ELOX
CUSIPN/A
CIKN/A
Phone858-909-0749

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$339.72 million
Next Earnings DateN/A
OptionableNot Optionable

Eloxx Pharmaceuticals (OTCMKTS:ELOX) Frequently Asked Questions

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELOX."

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals (OTCMKTS:ELOX) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.33) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.41) by $0.08. View Eloxx Pharmaceuticals' Earnings History.

What price target have analysts set for ELOX?

4 brokerages have issued 1 year target prices for Eloxx Pharmaceuticals' shares. Their predictions range from $10.00 to $31.00. On average, they anticipate Eloxx Pharmaceuticals' stock price to reach $21.00 in the next year. This suggests a possible upside of 122.7% from the stock's current price. View Analyst Price Targets for Eloxx Pharmaceuticals.

What is the consensus analysts' recommendation for Eloxx Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eloxx Pharmaceuticals.

What are Wall Street analysts saying about Eloxx Pharmaceuticals stock?

Here are some recent quotes from research analysts about Eloxx Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company's lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States. " (5/13/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $10/share is based on an equally-weighted composite of: (a) $8.43/share, as a 35x multiple of taxed and diluted $2.58 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $12.35/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (12/24/2018)

Has Eloxx Pharmaceuticals been receiving favorable news coverage?

News coverage about ELOX stock has trended somewhat positive this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Eloxx Pharmaceuticals earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near term.

Who are some of Eloxx Pharmaceuticals' key competitors?

What other stocks do shareholders of Eloxx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eloxx Pharmaceuticals investors own include Allena Pharmaceuticals (ALNA), Boeing (BA), ChemoCentryx (CCXI), Fate Therapeutics (FATE), Ciena (CIEN), CVS Health (CVS), JPMorgan Chase & Co. (JPM), Aurora Cannabis (ACBFF), Arbutus Biopharma (ABUS) and Aldeyra Therapeutics (ALDX).

Who are Eloxx Pharmaceuticals' key executives?

Eloxx Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert E. Ward, Chairman & CEO (Age 60)
  • Dr. Silvia Noiman, Founder & Director (Age 62)
  • Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)
  • Dr. Pedro Huertas, Chief Medical Officer (Age 63)
  • Dr. Colin Scott M.B., Ch.B., Medical Director (Age 66)

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.14%), Altshuler Shaham Ltd (2.36%), Meitav Dash Investments Ltd. (1.39%), Northern Trust Corp (0.80%), Geode Capital Management LLC (0.68%) and Charles Schwab Investment Management Inc. (0.32%). Company insiders that own Eloxx Pharmaceuticals stock include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Institutional Ownership Trends for Eloxx Pharmaceuticals.

Which institutional investors are selling Eloxx Pharmaceuticals stock?

ELOX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Meitav Dash Investments Ltd., BlackRock Inc., Charles Schwab Investment Management Inc. and Rhumbline Advisers. View Insider Buying and Selling for Eloxx Pharmaceuticals.

Which institutional investors are buying Eloxx Pharmaceuticals stock?

ELOX stock was bought by a variety of institutional investors in the last quarter, including Altshuler Shaham Ltd, Geode Capital Management LLC, State of Wisconsin Investment Board, Wells Fargo & Company MN, Northern Trust Corp and BNP Paribas Arbitrage SA. Company insiders that have bought Eloxx Pharmaceuticals stock in the last two years include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Insider Buying and Selling for Eloxx Pharmaceuticals.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $9.43.

How big of a company is Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals has a market capitalization of $339.72 million.

What is Eloxx Pharmaceuticals' official website?

The official website for Eloxx Pharmaceuticals is http://www.eloxxpharma.com/.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at 858-909-0749 or via email at [email protected]


MarketBeat Community Rating for Eloxx Pharmaceuticals (OTCMKTS ELOX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  182 (Vote Underperform)
Total Votes:  308
MarketBeat's community ratings are surveys of what our community members think about Eloxx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ELOX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel